Articles

CHICAGO—Patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMAs), especially decitabine, are more likely to achieve hematologic responses when treated with a greater number of cycles, investigators from Georgia Cancer Specialists in Marietta reported at the 2010 annual meeting of the American Society of Clinical Oncology.

Read More ›

Multiple professional and societal guidelines emphasize the importance of genetic counseling and testing for individuals at risk for hereditary breast cancer.1,2 For a woman newly diagnosed with breast cancer, information gained from genetic counseling and testing can directly impact her surgical management and treatment plan. Of the syndromes known to have an elevated risk of breast cancer, hereditary breast and ovarian cancer (HBOC) is the most common. HBOC is associated with mutations in the BRCA1 and BRCA2 genes. Read More ›


CHICAGO—Gene-expression profiling, combined with a novel chemoradiation regimen, may predict pathologic complete response in patients with esophageal cancer, according to new data presented at the 46th annual meeting in specific cancer populations. of the American Society of Clinical Oncology. New studies presented at this meeting highlighted several new “genetic fingerprinting” techniques that may improve and guide chemo therapy.

Read More ›

With community cancer centers facing rising costs and declining revenues, finding more efficient ways to run a practice is critical. In this interview, Cathy Maxwell, RN, OCN, director of clinical operations at Advanced Medical Specialties in Miami, Florida, discusses how community cancer centers can make the most efficient use of chemotherapy nurses by efficient scheduling and how this not only increases nurse and patient satisfaction but also reduces costs.

Read More ›

Patients with chronic myeloid leukemia (CML) who have maintained complete molecular remission (CMR) for at least 2 years can safely discontinue imatinib therapy, French researchers report.
 
Read More ›

Many patients diagnosed with skin cancer do not know whether they have melanoma or nonmelanoma skin cancer and, as a result, may have a poor sense of the measures they need to take to reduce the risk of future skin cancers, a study by an investigator at the Cancer Institute of New Jersey, New Brunswick, indicates.
 
Read More ›

In a long-term study of men who underwent robot-assisted radical prostatectomy (RARP) nearly 87% had no recurrence of the disease after 5 years.
 
The study cohort included 1384 men who were diagnosed with moderately aggressive localized prostate cancer and underwent RARP between September 2001 and May 2005 at a tertiary center. Their average age was 60 years.
 
Read More ›

Researchers identified an association between type 2 diabetes and colorectal cancer (CRC) among men. The association did not hold for women. The new study, published in the October issue of Gastroenterology, found that the risk existed regardless of insulin use. Insulin use, in fact, was found to be associated with a slight but not substantially increased risk of CRC.
 
Read More ›

Use of hospice care for men with prostate cancer has increased significantly over the past 2 decades, but most wait too long to enroll, when they cannot take full advantage of the palliative care services offered, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

Read More ›

Cancer patients with pain or depression often also have physical symptoms, such as fatigue, dry mouth and nausea, that can cause disability, a new study shows.
 
“This study strengthens the case for improving the recognition and treatment of somatic symptoms in patients with cancer,” the researchers said in a news release.
 
Read More ›

Page 362 of 377


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: